Literature DB >> 22800575

Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug.

Wenda C Carlyle1, James B McClain, Abraham R Tzafriri, Lynn Bailey, Brett G Zani, Peter M Markham, James R L Stanley, Elazer R Edelman.   

Abstract

Current drug eluting stent (DES) technology is not optimized with regard to the pharmacokinetics of drug delivery. A novel, absorbable-coating sirolimus-eluting stent (AC-SES) was evaluated for its capacity to deliver drug more evenly within the intimal area rather than concentrating drug around the stent struts and for its ability to match coating erosion with drug release. The coating consisted of absorbable poly-lactide-co-glycolic acid (PLGA) and crystalline sirolimus deposited by a dry-powder electrostatic process. The AC-SES demonstrated enhanced drug stability under simulated use conditions and consistent drug delivery balanced with coating erosion in a porcine coronary implant model. The initial drug burst was eliminated and drug release was sustained after implantation. The coating was absorbed within 90 days. Following implantation into porcine coronary arteries the AC-SES coating is distributed in the surrounding intimal tissue over the course of several weeks. Computational modeling of drug delivery characteristics demonstrates how distributed coating optimizes the load of drug immediately around each stent strut and extends drug delivery between stent struts. The result was a highly efficient arterial uptake of drug with superior performance to a clinical bare metal stent (BMS). Neointimal thickness (0.17±0.07 mm vs. 0.28±0.11 mm) and area percent stenosis (22±9% vs. 35±12%) were significantly reduced (p<0.05) by the AC-SES compared to the BMS 30 days after stent implantation in an overlap configuration in porcine coronary arteries. Inflammation was significantly reduced in the AC-SES compared to the BMS at both 30 and 90 days after implantation. Biocompatible, rapidly absorbable stent coatings enable the matching of drug release with coating erosion and provide for the controlled migration of coating material into tissue to reduce vicissitudes in drug tissue levels, optimizing efficacy and reducing potential toxicity.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22800575      PMCID: PMC4637970          DOI: 10.1016/j.jconrel.2012.07.004

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  23 in total

1.  In vitro and in vivo changes to PLGA/sirolimus coating on drug eluting stents.

Authors:  Tingfei Xi; Runlin Gao; Bo Xu; Liang Chen; Tong Luo; Jing Liu; Yan Wei; Shengping Zhong
Journal:  Biomaterials       Date:  2010-04-10       Impact factor: 12.479

2.  Vascular response to a third generation everolimus-eluting stent.

Authors:  Gregory J Wilson; Barbara A Huibregtse; Elizabeth A Stejskal; Jody Crary; Ruth M Starzyk; Keith D Dawkins; James J Barry
Journal:  EuroIntervention       Date:  2010-09       Impact factor: 6.534

Review 3.  Coronary stents: looking forward.

Authors:  Scot Garg; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2010-08-31       Impact factor: 24.094

4.  Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production.

Authors:  M G Attur; R Patel; G Thakker; P Vyas; D Levartovsky; P Patel; S Naqvi; R Raza; K Patel; D Abramson; G Bruno; S B Abramson; A R Amin
Journal:  Inflamm Res       Date:  2000-01       Impact factor: 4.575

5.  Polymers for drug eluting stents.

Authors:  Ted Parker; Vipul Davé; Robert Falotico
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

6.  Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial.

Authors:  A Kastrati; J Mehilli; J Dirschinger; F Dotzer; H Schühlen; F J Neumann; M Fleckenstein; C Pfafferott; M Seyfarth; A Schömig
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

Review 7.  Endothelial dysfunction following drug-eluting stent implantation: a systematic review of the literature.

Authors:  Yoshiyasu Minami; Hideaki Kaneda; Masahiro Inoue; Masayasu Ikutomi; Toshihiro Morita; Toshiaki Nakajima
Journal:  Int J Cardiol       Date:  2012-03-28       Impact factor: 4.164

8.  Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients.

Authors:  Yoritaka Otsuka; Shigeru Saito; Masato Nakamura; Hideo Shuto; Kazuaki Mitsudo
Journal:  Catheter Cardiovasc Interv       Date:  2011-11-02       Impact factor: 2.692

9.  In vivo evaluation of a biolimus eluting nickel titanium self expanding stent with overlapping balloon expandable drug eluting and bare metal stents in a porcine coronary model.

Authors:  Mehmet Cilingiroglu; James Elliott; Pramod Sangi; Holly Matthews; Fermin Tio; Brett Trauthen; John Elicker; Steven R Bailey
Journal:  EuroIntervention       Date:  2009-01       Impact factor: 6.534

Review 10.  A review of current devices and a look at new technology: drug-eluting stents.

Authors:  Gaku Nakazawa; Aloke V Finn; Frank D Kolodgie; Renu Virmani
Journal:  Expert Rev Med Devices       Date:  2009-01       Impact factor: 3.166

View more
  13 in total

1.  Drug deposition in coronary arteries with overlapping drug-eluting stents.

Authors:  Farhad Rikhtegar; Elazer R Edelman; Ufuk Olgac; Dimos Poulikakos; Vartan Kurtcuoglu
Journal:  J Control Release       Date:  2016-07-16       Impact factor: 9.776

Review 2.  Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review.

Authors:  David Marlevi; Elazer R Edelman
Journal:  J Am Coll Cardiol       Date:  2021-05-18       Impact factor: 24.094

3.  Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings.

Authors:  Abraham R Tzafriri; Fernando Garcia-Polite; Xiaojian Li; John Keating; Josep-Maria Balaguer; Brett Zani; Lynn Bailey; Peter Markham; Timothy C Kiorpes; Wenda Carlyle; Elazer R Edelman
Journal:  J Control Release       Date:  2018-02-05       Impact factor: 9.776

Review 4.  Endovascular Drug Delivery and Drug Elution Systems: First Principles.

Authors:  Abraham Rami Tzafriri; Elazer Reuven Edelman
Journal:  Interv Cardiol Clin       Date:  2016-06-21

5.  Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation.

Authors:  Hidetoshi Chibana; Hidemi Kajimoto; Takafumi Ueno; Shinji Yokoyama; Ken-Ichiro Sasaki; Masanori Ohtsuka; Hiroshi Koiwaya; Takaharu Nakayoshi; Yoshiaki Mitsutake; Naoki Itaya; Masahiro Sasaki; Yoshihiro Fukumoto
Journal:  Heart Vessels       Date:  2017-01-23       Impact factor: 2.037

6.  Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics.

Authors:  Abraham R Tzafriri; Sahil A Parikh; Elazer R Edelman
Journal:  J Control Release       Date:  2019-08-17       Impact factor: 9.776

7.  Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).

Authors:  Alexandra J Lansky; Adnan Kastrati; Elazer R Edelman; Helen Parise; Vivian G Ng; John Ormiston; William Wijns; Robert A Byrne
Journal:  Am J Cardiol       Date:  2015-12-07       Impact factor: 2.778

Review 8.  Bioresorbable Scaffold-Based Controlled Drug Delivery for Restenosis.

Authors:  Belay Tesfamariam
Journal:  J Cardiovasc Transl Res       Date:  2018-10-26       Impact factor: 4.132

9.  Similarities and differences in coatings for magnesium-based stents and orthopaedic implants.

Authors:  Jun Ma; Marc Thompson; Nan Zhao; Donghui Zhu
Journal:  J Orthop Translat       Date:  2014-04-05       Impact factor: 5.191

Review 10.  Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary Stents.

Authors:  C M McKittrick; S Kennedy; K G Oldroyd; S McGinty; C McCormick
Journal:  Ann Biomed Eng       Date:  2015-09-18       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.